Merck lowers profit outlook, partly due to $200 million expected tariff hit
Merck on Thursday lowered its full-year profit guidance, citing $200 million in estimated costs for tariffs and a charge tied to a recent deal.
The company now expects its 2025 adjusted earnings to come in between $8.82 and $8.97, down slightly from a previous outlook of 8.88 to $9.03 per share.
The company said the expected tariff charge primarily reflects levies between the U.S. and China, and Canada and Mexico to a lesser degree. Merck has built a robust presence in China, which is considered one of the company's most important markets and is home to some of its partners and manufacturing and research and development sites.
Merck noted that the new outlook does not account for President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S., which is prompting some drugmakers to bolster their U.S. manufacturing footprints.
That includes Merck, which has invested $12 billion in U.S. manufacturing and research and development and expects to put more than $9 billion more into the country by the end of 2028.
But the guidance does include a one-time charge of roughly 6 cents per share related to the company's license agreement with Hengrui Pharma, which it announced in March.
Merck reiterated its full-year sales forecast of between $64.1 billion and $65.6 billion.
Also on Thursday, the drugmaker reported first-quarter revenue and profit that beat expectations, as it said it saw strength in its oncology portfolio and animal health products.
Merck also cited "increasingly meaningful" sales contributions from two recently launched drugs. They are Winrevair, which is used to treat a rare, deadly lung condition, and Capvaxive, a vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and lung infection.
Sales of those drugs will likely be critical to Merck's efforts to offset losses from its top-selling cancer therapy Keytruda, which will lose exclusivity in 2028.
Here's what Merck reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:
The company posted net income of $5.08 billion, or $2.01 per share, for the quarter. That compares with a net income of $4.76 billion, or $1.87 per share, during the year-earlier period.
Excluding acquisition and restructuring costs, Merck earned $2.22 per share for the first quarter.
Merck raked in $15.53 billion in revenue for the quarter, down 2% from the same period a year ago.
Merck's pharmaceutical unit, which develops a wide range of drugs, booked $13.64 billion in revenue during the first quarter. That's down 3% from the same period a year ago.
Keytruda recorded $7.21 billion in revenue during the quarter, up just 4% from the year-earlier period.
That increase was driven by higher uptake of Keytruda for earlier-stage cancers and strong demand for the drug for metastatic cancers, which spread to other parts of the body. Still, sales came under the $7.43 billion that analysts had expected, according to StreetAccount estimates.
Notably, Merck continued to see trouble with China sales of Gardasil, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S.
In February, Merck announced a decision to halt shipments of Gardasil into China beginning that month and going through at least mid-2025. Investors will likely be looking for updates on that effort during the earnings call on Thursday.
The Chinese market makes up the majority of the blockbuster shot's international revenue. Merck is hoping that Gardasil's expanded approval for men ages 9 to 26 in China will help boost uptake of the shot.
Gardasil raked in $1.33 billion in sales, down 41% from the first quarter of 2024 primarily due to lower demand in China. That's below the $1.45 billion that analysts were expecting, according to StreetAccount estimates.
China has retaliated with tariffs of 125% on goods from the U.S. Some experts said China's tariffs on U.S. products could lead to increased prices or limited supply of some popular Western medicines for Chinese patients, Reuters reported.
Merck's animal health division, which develops vaccines and medicines for dogs, cats and cattle, posted nearly $1.59 billion in sales, up 5% from the same period a year ago. The company said higher demand for livestock products and sales from Elanco's aqua business, which it acquired last year, drove that growth.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Trump's ‘Big Beautiful Bill' Would Slash Medicare & SNAP: 3 Moves Retirees Should Make Now
President Donald Trump's 'one big beautiful bill' has passed in the House and is now awaiting Senate approval. If passed, Trump's signature bill would extend the tax cuts granted by the 2017 Tax Cuts and Jobs Act and add additional tax cuts. While this might be welcome news to many, the bill also includes changes to Medicaid and the Supplemental Nutrition Assistance Program (SNAP) that could threaten seniors' access to these programs. Find Out: Read Next: 'The 'one big beautiful bill' passed by the House of Representatives, if it were passed into law today, would cut Medicaid and SNAP by a combined $1 trillion,' said Chris Orestis, president of Retirement Genius. 'In addition, because of the increase to federal debt of as much as $5 trillion, the bill would trigger an automatic reduction in Medicare funding of $500 billion,' he continued. 'This would represent the largest cut to social services and health insurance for the poor, disabled, children and the elderly in U.S. history.' Here's a look at the changes retirees can make now to secure care and avoid benefit disruptions if the bill were to pass. Before changes go into effect, check with your healthcare providers to ensure there won't be any interruption to your care if there are cuts to Medicaid. 'Check with your healthcare provider to see if they might cut back on services or cease accepting Medicaid-funded patients, and contact any nursing home where you or a loved one may reside to find out if they will be reducing the number of patients they can support — or even [if they are] possibly planning to close,' Orestis said. Knowing this ahead of time will allow you to find alternative care providers before it's too late. Learn More: If you are reliant on SNAP, start searching for alternatives that may be able to provide food assistance in the event your benefits are reduced or cut. 'Make sure you know where there are local support services through community or faith-based organizations to replace lost access through SNAP,' Orestis said. Many retirees plan to 'spend down' their savings so that they qualify for Medicaid to pay for their long-term care. However, this may no longer be a viable option. 'If you are considering going onto Medicaid for long-term care and are preparing to engage the 'spend down' process to impoverish yourself and get below the poverty level to qualify, you may want to reconsider that strategy, and instead look to leverage private pay resources to pay for your care,' Orestis said. 'If you are on Medicaid, you will primarily be reliant on nursing homes for your care, and their ability to withstand these cuts will be very challenging and up in the air,' he continued. 'If you are private pay, you are in control and can decide where and when you will receive care, such as at home or an assisted living community not funded by Medicaid.' Strategies to stay private pay for long-term care would include long-term care insurance, annuities, a life insurance settlement, a reverse mortgage or VA benefits. Editor's note on political coverage: GOBankingRates is nonpartisan and strives to cover all aspects of the economy objectively and present balanced reports on politically focused finance stories. You can find more coverage of this topic on More From GOBankingRates 7 Things You'll Be Happy You Downsized in Retirement This article originally appeared on Trump's 'Big Beautiful Bill' Would Slash Medicare & SNAP: 3 Moves Retirees Should Make Now
Yahoo
23 minutes ago
- Yahoo
ECB's Escriva sees scope for minor monetary policy easing
MADRID (Reuters) -The path of monetary policy easing in the euro zone could require further adjustments if the current macroeconomic and inflation outlooks are confirmed, ECB policymaker Jose Luis Escriva said. Last week, the ECB cut interest rates and hinted at a pause after inflation in the euro zone returned to its 2% target. Escriva, who is also Bank of Spain Governor, said in an interview to newspaper El Pais on Sunday that he "was very comfortable" with the current, gradual approach of successive 25-basis-point rate cuts. "Our central scenario – GDP growth of around 1%, inflation of 2% – could require some fine-tuning if it is confirmed," Escriva. The ECB has cut rates 2 percentage points since last June, to prop up a euro zone economy also hit by erratic U.S. economic and trade policies. Escriva said confidence in the dollar and U.S. assets had decreased since U.S. President Donald Trump took office and that since April, the dollar had not been a "safe haven" and its dominance as a global reserve currency appeared to have peaked. He also said the Bank of Spain was expected to revise downwards on Tuesday the forecast for Spanish economic growth by a few decimal points from the current 2.7% for 2025. Sign in to access your portfolio
USA Today
26 minutes ago
- USA Today
Trump's dysfunctional government can learn from these Republican governors
Trump's dysfunctional government can learn from these Republican governors | Opinion You might not have noticed, but there are Republicans doing the job of governing. They're just not in the federal government. Show Caption Hide Caption Six takeaways from the President Donald Trump, Elon Musk feud From disappointment to threats, here are six takeaways from the public spat between President Donald Trump and Elon Musk. President Donald Trump and congressional Republicans are struggling to do their jobs because they are losing focus on what they were elected to do. They are creating political sideshows and distractions from the issues that truly matter to Americans, and the issues that voters wanted Trump to fix. Instead of fixing the economy, for example, Trump is locked in a social media battle with Elon Musk. Why? Republicans in control of the federal government should take a note from popular GOP governors who are delivering on what voters actually want without all of the noise that is engulfing the presidency and Congress. Opinion: Musk is angry Trump used him. I'm frustrated we're focusing on the wrong thing. Republican governors succeed in spite of Trump Trump has made progress on securing the border, despite his deportation struggles, but the economy is where he struggles. His unpredictable and ill-advised tariff policy has investors worried, and his administration is pushing a bill that would raise the country's deficit. The old adage 'it's the economy, stupid' rings true even today. If Trump cannot handle the basics of the job, then Americans are unlikely to give him leeway on other issues. In contrast, Florida Gov. Ron DeSantis is more popular than Trump in the Sunshine State and is overseeing a strong economic run while presiding over a strong public school system. Florida's job growth is outpacing the national average. Georgia Gov. Brian Kemp is another example. He enjoys extraordinarily high approval ratings, even though Trump had a narrow victory in the state in 2024. He's done so on the back of good job creation marks and, again, a strong public school system. These are two Republican governors doing the job we need the federal GOP to do, instead of the bickering we're seeing unfold on social media. This isn't to say that either of those two governors don't take swings in the culture war. DeSantis is probably best known for his actions against Disney and other social debates. Kemp also has a history of fighting "woke" and dabbling in the culture wars. But in surrounding themselves with competent allies and running the government well, voters give them a longer leash. Trump should follow DeSantis, Kemp's lead: Focus on what voters need The lesson here for Trump is to take care of the basic issues that impact voters, then he can get bogged down in his culture war stances. Both Kemp and DeSantis have gotten away with their antics because they are competent executives. Opinion: There is no 'reverse discrimination,' people. There is only discrimination. In state governments, this includes going to the DMV, the quality of public schools and paying taxes. If these types of experiences are painless, people have a more positive view of the government. Federally, this is reflected in the economy, as people's daily lives are most significantly impacted by the state of the economy. Culture war issues matter at the margins, but people broadly vote based on the economy. Because Trump is struggling with the economy, his actions in other areas are a glaring distraction. He could stand to ask governors like DeSantis and Kemp about how to lead along conservative principles without all the mess and failure. Dace Potas is an opinion columnist for USA TODAY and a graduate of DePaul University with a degree in political science.
